- Previous Close
177.85 - Open
176.60 - Bid 176.31 x 100
- Ask 179.09 x 100
- Day's Range
173.65 - 181.69 - 52 Week Range
99.00 - 219.34 - Volume
180,349 - Avg. Volume
225,476 - Market Cap (intraday)
5.122B - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
100.06 - EPS (TTM)
1.78 - Earnings Date Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
207.78
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: KRYS
View More
Performance Overview: KRYS
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRYS
View MoreValuation Measures
Market Cap
5.12B
Enterprise Value
4.54B
Trailing P/E
100.06
Forward P/E
31.95
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.73
Price/Book (mrq)
5.78
Enterprise Value/Revenue
18.80
Enterprise Value/EBITDA
25.08
Financial Highlights
Profitability and Income Statement
Profit Margin
21.68%
Return on Assets (ttm)
4.58%
Return on Equity (ttm)
6.38%
Revenue (ttm)
241.52M
Net Income Avi to Common (ttm)
52.37M
Diluted EPS (ttm)
1.78
Balance Sheet and Cash Flow
Total Cash (mrq)
588.32M
Total Debt/Equity (mrq)
0.84%
Levered Free Cash Flow (ttm)
42.38M
Research Analysis: KRYS
View MoreCompany Insights: KRYS
KRYS does not have Company Insights
Research Reports: KRYS
View MoreLowering target price to $187.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $187.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $197.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $197.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $183.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $183.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $185.00
KRYSTAL BIOTECH INC has an Investment Rating of HOLD; a target price of $185.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target